The Golden Retriever Lifetime Study, launched in 2012 by the Morris Animal Foundation, was designed to untangle the dietary, genetic, and environmental risk factors behind four major canine cancers: lymphoma, hemangiosarcoma, high-grade mast cell tumors, and osteosarcoma. Golden Retrievers were chosen deliberately. Roughly half of all deaths in the breed are attributed to cancer, according to data from the Veterinary Medical Database, and the breed shows a markedly elevated incidence of hemangiosarcoma and lymphoma. Because privately owned dogs were enrolled young, between six months and two years of age, and followed with annual questionnaires, veterinary examinations, and biological sampling, the study captures lifestyle exposures years before any diagnosis is made.

In the new analysis, Dennis Ronzani of Ross University School of Veterinary Medicine and Sarah E. Hooper of Arkansas State University examined the activity and lifestyle questionnaire responses of 3,044 purebred Golden Retrievers across the first seven years of the study. During that window, 277 dogs were diagnosed with cancer, with a median age at diagnosis of 6.1 years. The researchers asked a deceptively simple question: could the exercise habits reported by owners, on their own, distinguish dogs that would develop cancer from those that would not?

Answering that question required overcoming a statistical obstacle that has long discouraged researchers from mining longitudinal cohort data. Standard machine learning algorithms assume that every data point is independently sampled, an assumption shattered by repeated annual measurements of the same dog. Classical models, meanwhile, struggle when the number of observations is smaller than the number of predictors. The team turned to a hybrid method called the BiMM forest, developed by Speiser and colleagues, which combines a generalized linear mixed model with a random forest algorithm. This architecture is specifically built to handle clustered, high-dimensional data with nonlinear relationships and interactions between predictors, making it well suited to serial owner reports spanning multiple years.

The researchers built two models. The first used only questions asked consistently from year zero through year seven; the second incorporated additional questions about the pace and duration of exercise that the Morris Animal Foundation added to the questionnaire starting in year three. The difference in performance was dramatic. The years zero through seven model achieved an overall accuracy of just 68.2 percent, while the years three through seven model reached 80.7 percent accuracy, an F1 score of 74.9 percent, and a fair area under the receiver operating characteristic curve of 0.763. The lesson was clear: knowing how briskly and how long a dog exercises carries far more predictive signal than knowing only which activities it performs.

Ranking the predictors by their mean decrease in Gini importance, the team found that the top variables were year in study, exercise frequency, exercise pace, exercise duration, and the frequency of swimming in both warm and cold weather, followed by the owner-reported overall activity level. Four of the ten most important predictors related directly to the frequency and duration of aerobic activity. Perhaps most surprising, the specific type of exercise and the surface on which it took place ranked low in importance. It was the rhythm and intensity of movement, not the movement itself, that carried the strongest association with cancer status.

The data also revealed a poignant behavioral shift after diagnosis. Owners of dogs diagnosed with cancer reported an 8 to 10 percent increase in exercise frequency in the years following the diagnosis, and a 15.6 to 68.88 percent increase in cold weather swimming, while warm weather swimming declined by 2.0 to 13.9 percent. At the same time, exercise pace and duration fell, with dogs diagnosed in year four showing a 7.8 percent reduction in duration and overall activity levels declining by as much as 15.5 percent. The authors suggest this pattern may reflect veterinary recommendations or owner research into the benefits of exercise for canine cancer patients, mirroring the well-documented phenomenon in which roughly three out of four human cancer survivors meet physical activity guidelines after diagnosis.

The findings resonate strongly with human oncology research. Moderate-to-vigorous physical activity is firmly associated with reduced risk of colon, kidney, liver, and mammary cancers in people, and has been shown to delay cancer onset even in women genetically predisposed to breast cancer. Laboratory studies add mechanistic weight: moderate-intensity exercise inhibits cancer cell proliferation and induces apoptosis in animal models, whereas strenuous activity can, in some contexts, promote tumor growth. Notably, most Golden Retrievers in the study exercised at a brisk walking pace for 10 to 60 minutes per session, which qualifies as moderate intensity under the Physical Activity Guidelines for Americans, yet the total weekly volume often fell short of the 150 to 300 minutes recommended for humans, echoing the finding that three quarters of the US population also fails to meet those guidelines.

The swimming data carry their own intriguing, and cautionary, dimension. Dogs diagnosed with cancer swam slightly more often in cold weather before diagnosis, and cold weather swimming rose sharply afterward, possibly reflecting the growing popularity of aquatic therapy and underwater treadmills for canine rehabilitation. But water quality introduces a potential confound. The US Environmental Protection Agency reports that more than 13 million acres of lakes and ponds are impaired by pollution, and epidemiological studies in humans have linked disinfection by-products such as trihalomethanes in chlorinated pools to increased cancer risk. One prior study even found that dogs with urothelial cell carcinoma were more likely to have swum in pools than cancer-free dogs, a connection the authors say warrants closer investigation.

The study has limitations that its authors acknowledge candidly. Because a data embargo restricted the analysis to the first seven years, many dogs had not yet reached the typical age of cancer diagnosis, and fewer than 10 percent of the cohort had a neoplastic diagnosis, too few to build models for individual cancer types. All cancers were therefore grouped together, and missing body condition score data, available for only some dogs and years, prevented the team from accounting for obesity, itself a known risk factor for certain canine cancers. Still, the authors argue that the results point toward a future in which veterinarians can offer evidence-based exercise guidance for dogs, focused on frequency, duration, and pace rather than activity type, and in which cumulative lifestyle exposures, shaped by owner behavior and environment, take their rightful place in canine cancer risk assessment. As more years of Golden Retriever Lifetime Study data become available, the same machine learning approach may reveal whether these patterns hold for specific tumors, and whether adjusting a dog’s exercise routine could genuinely shift its cancer risk.

Subject of Research: Physical activity patterns as predictors of cancer development in Golden Retrievers

Article Title: Physical activity predictors of cancer in Golden Retrievers: it's about frequency and intensity, not type

Article References: Ronzani, D., & Hooper, S. E. (2025). Physical activity predictors of cancer in Golden Retrievers: it's about frequency and intensity, not type. Veterinary Oncology, 2(1), Article 11. https://doi.org/10.1186/s44356-025-00024-5

Image Credits: AI Generated

DOI: 10.1186/s44356-025-00024-5

Keywords: Golden Retriever, canine cancer, machine learning, physical activity, Golden Retriever Lifetime Study, veterinary oncology, BiMM forest, exercise frequency, exercise intensity, swimming, cancer risk factors, longitudinal study

Mast cell tumours are the most frequently diagnosed cutaneous malignancy in dogs, accounting for an estimated 16 to 21 percent of all skin neoplasms. They arise from mast cells, immune cells rich in inflammatory mediators such as histamine and heparin, and typically present as masses in the skin or the tissue beneath it. Their biological behaviour spans an extraordinary range: some are cured permanently by simple surgical excision, while others ulcerate, recur locally and spread to lymph nodes, liver and spleen. Paraneoplastic effects driven by the release of mast cell granules can produce itching, bruising, skin swelling and gastrointestinal signs, complicating the clinical picture. Two histological grading systems, the three-tier Patnaik scheme and the two-tier Kiupel scheme, are widely used to predict behaviour, and both have been shown to be consistently prognostic, particularly when applied together.

Golden Retrievers have repeatedly been identified as a breed at increased risk of MCTs, and germline genetic studies have pinpointed risk variants in genes including GNAI2 and a hyaluronidase gene in US Golden Retrievers. Yet until now, no epidemiological study had specifically characterised MCT frequency, clinical features and survival within the breed in the United States. The GRLS, a prospective cohort of 3,044 Golden Retrievers enrolled between June 2012 and April 2015 and balanced by sex across five geographic regions, offered a uniquely powerful opportunity. Dogs were followed annually with owner and veterinarian questionnaires, biological samples and a dedicated biopsy submission pathway, with histopathology reviewed by two blinded veterinary pathologists. The study’s primary cancer endpoints include haemangiosarcoma, lymphoma, osteosarcoma and high-grade MCT, with high grade defined as Patnaik grade 3 or Kiupel high.

The headline numbers are striking. Of the 3,044 dogs, 164, or 5.39 percent, were diagnosed with a total of 234 mast cell tumours, yielding an incidence rate of 5.58 per 1,000 dog years at risk. A lifetable analysis revealed that young dogs were rarely affected: 99.1 percent of the cohort reached five years of age without an MCT diagnosis. Annual incidence risk peaked at 1.39 percent in dogs aged greater than eight to nine years, before declining in the oldest age groups. The authors note that this decline mirrors patterns seen in other veterinary and even human cancers, where incidence falls in extreme old age, possibly reflecting cellular senescence, stem cell exhaustion or a cancer-resistant phenotype, though diagnostic bias in geriatric patients may also contribute.

Compared with incidence figures from a mixed-breed insured population in Sweden, the Golden Retriever rate appears up to tenfold higher, which the researchers interpret as evidence of a genuine and substantial breed predisposition rather than an artefact of geography or study design. The practical message for owners is clear: vigilance for skin masses, particularly as dogs enter middle and older age, is warranted, and any new lump should prompt veterinary investigation rather than a wait-and-see approach. The median age at first diagnosis in the cohort was just over eight years.

The tumours themselves were predominantly low grade. Cutaneous tumours accounted for 70.5 percent of events and subcutaneous tumours for 16.7 percent, with the remainder being metastatic entries, mucosal or visceral primaries, or digital masses. The most common anatomical locations were the torso, limbs and head and neck, consistent with distributions reported in multi-breed populations. Histopathological grading was available for nearly all cutaneous tumours, and the most frequent grade was the intermediate-low P2KL category. Overall, only 47 of the 234 tumours, or 20.1 percent, met the study’s high-grade definition, a proportion consistent with previous reports of 22 to 26 percent high-grade disease in broader populations. Notably, the findings do not support earlier suggestions that Golden Retrievers are disproportionately prone to high-grade tumours.

Recurrence and spread were comparatively uncommon. Most dogs, 84.2 percent, had a solitary tumour, while 15.9 percent developed new de novo masses at distinct sites, with a median interval of 368 days between the first and subsequent tumours. Local recurrence occurred in just under five percent of cases, and documented metastasis in 9.8 percent, most often to lymph nodes. Critically, every dog with metastatic disease had at least one high-grade tumour; no dog with only low-grade MCTs was found to have spread. The authors suggest this could influence clinical staging recommendations, since extensive staging appears to have low diagnostic yield in low-risk patients, although the absence of standardised staging protocols means some metastases may have gone undetected.

The survival analysis produced the study’s most reassuring result. Median lifespan was 11.68 years in dogs diagnosed with MCT and 11.75 years in the remaining cohort, a difference that was not statistically significant. Median survival time from first MCT diagnosis to death from any cause was 1,367 days, and only 19 dogs, or 11.6 percent, had MCT recorded as their cause of death. Overall survival probabilities after diagnosis were 81.7 percent at one year, 70.0 percent at two years and 40.6 percent at five years. When the analysis was stratified, however, the prognostic weight of tumour biology became evident: the presence of metastasis, a high histological grade, or local recurrence were each associated with statistically significantly reduced survival, while the development of additional de novo tumours was not. Nearly 90 percent of the dogs that died from their disease had at least one high-grade tumour.

The researchers acknowledge several limitations. Cohort recruitment relied on word-of-mouth and snowball sampling, dogs were required to have three-generation pedigrees, and participating owners were highly engaged, with subsidised histopathology likely boosting diagnostic rates relative to the wider population. Treatment details were largely unavailable, precluding analysis of therapeutic impact, and the number of MCT-related deaths was too small for multivariable modelling. Nevertheless, the study’s general-practice setting gives it a realism that insurance-claim and referral-based studies lack. Its overall message is one of measured optimism: for most Golden Retrievers, a mast cell tumour diagnosis is not life-limiting, low-grade disease carries an excellent prognosis with prompt and appropriate management, and the findings justify early investigation and treatment of skin masses rather than fatalism. As the GRLS cohort continues to yield data, it is cementing its role as one of the most valuable resources in comparative oncology, with implications that may ultimately extend to human mast cell disorders and cancer research more broadly.

Subject of Research: Epidemiology, clinical features and survival of mast cell tumours in Golden Retrievers enrolled in the Golden Retriever Lifetime Study

Article Title: Mast cell tumours in the Golden Retriever Lifetime Study: a cohort study assessing frequency, clinical features and survival

Article References: Stratton, Z. V., Brodbelt, D. C., Guillén, A., O’Neill, D. G., Labadie, J., Swafford, B., & Taylor, C. (2026). Mast cell tumours in the Golden Retriever Lifetime Study: a cohort study assessing frequency, clinical features and survival. Veterinary Oncology, 3(1), Article 10. https://doi.org/10.1186/s44356-026-00060-9

Image Credits: AI Generated

DOI: 10.1186/s44356-026-00060-9

Keywords: Golden Retriever, mast cell tumour, canine cancer, veterinary oncology, Golden Retriever Lifetime Study, dog lifespan, histological grading, Kiupel, Patnaik, metastasis, incidence, survival analysis